Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Recruiting · NCT05798897 · Registry updated 2026-09-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma | Disease Attributes, Hemic and Lymphatic Diseases, Hodgkin Lymphoma, Adult, Hodgkins lymphoma, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Recruiting | Phase 1 | 2026-09-15 | NCT05798897 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Marker Therapeutics, Inc. | 3 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope | Duarte | United States | 238 |
| Colorado Blood Cancer Institute (Sarah Cannon) | Denver | United States | 2 |
| Cornell | New York | United States | 1 |
| Sarah Cannon Research Institute at St. David's South Austin | Austin | United States | 1 |
| University of Colorado | Aurora | United States | 147 |
| University of Kansas Medical Center | Kansas City | United States | 240 |
| University of Wisconsin Carbone Cancer Center | Madison | United States | 58 |